Dr. Deborah W. Knapp's lab at Purdue University focuses on improving cancer treatment through innovative research on immune cell responses in both dogs and humans with invasive urinary bladder cancer. By studying naturally-occurring bladder cancer in dogs, the lab aims to advance immunotherapy techniques that can enhance outcomes in human patients. This research not only contributes to better therapy options for bladder cancer but also aims to harness the canine model to explore solutions for other types of cancer.

Dr. Mark C Hall's research lab at Purdue University focuses on understanding how a specific protein, Cdc14 phosphatase, affects the virulence and drug resistance of fungal pathogens, particularly Candida species. The lab explores how this protein influences cell wall integrity, fungal growth, and responses to antifungal drugs, with the aim of identifying new targets for antifungal therapies. By studying the molecular mechanisms behind Cdc14's role, the lab seeks to contribute to the development of effective treatments for life-threatening fungal infections, especially in immune-compromised patients.

Dr. Meng Cui's lab focuses on advancing imaging technologies for neuroscience, specifically through the development of a Light Pipe Microscope (LPM) designed for high-resolution imaging of the mammalian brain. The lab's work aims to enhance our understanding of neural circuits by enabling the observation of brain activity over large areas at a cellular level. By combining engineering innovations and neuroscience, they strive to provide low-cost, high-quality imaging solutions that can be broadly adopted to study brain function and cognition.

Dr. Vincent Davisson's lab at Purdue University is focused on developing new treatments to counteract toxic cyanide exposure. The research aims to improve existing countermeasures and explore combinations of agents that can efficiently help individuals affected by chemical threats. By using various animal models, the lab works to ensure that these interventions are both safe and effective in emergency situations, ultimately aiming to protect human health from chemical hazards.

Dr. Danzhou Yang's lab at Purdue University focuses on developing innovative therapies for cancer and inflammatory diseases. The lab investigates the regulation of gene expression, specifically targeting a unique structure in DNA known as a G-quadruplex to suppress the overexpression of a protein called PDGFR-beta, which is implicated in various diseases. By designing and synthesizing small molecular compounds that interact with this structure, the lab aims to create more effective treatments for conditions where PDGFR-beta is a key player.

Dr. Bridgette Lynne Kelleher's lab at Purdue University focuses on improving the development and care of young children with rare neurogenetic conditions. Using innovative telehealth technology, the lab collects valuable data on children's behaviors and physiological responses to understand their unique developmental trajectories. This work aims to establish better assessment tools and treatment standards for affected families, helping to enhance the quality of life for these children.

Dr. Chi Hwan Lee's research lab at Purdue University is focused on developing innovative smart soft contact lenses designed to monitor intraocular pressure continuously, particularly for glaucoma patients. These contact lenses aim to be comfortable and safe for long-term wear, allowing more accurate tracking of eye pressure to prevent vision loss. The lab combines biomedical engineering principles with advanced material science to create a new generation of ocular devices that could also benefit patients with other eye diseases.

Dr. Kevin J. Otto's research lab at Purdue University focuses on using advanced electrical microstimulation techniques to manipulate neural activity in the central nervous system. The team develops and optimizes microelectrode arrays to improve treatments for neurological conditions. By creating safe and effective neuroprosthetic technologies, they aim to enhance the quality of life for individuals with nervous system injuries or diseases.

Dr. Jianing Li's lab at Purdue University focuses on developing innovative peptide-based therapies for Alzheimer's Disease (AD) and related dementias (ADRD). By using advanced generative artificial intelligence (AI), the lab aims to design more effective and safer peptide drugs that can better target the causes of these diseases. The research not only seeks to improve drug development processes but also strives to make peptide therapeutics more accessible to researchers and healthcare providers.

Dr. Jonathan Patrick Schlebach's lab at Purdue University focuses on understanding how certain proteins, specifically membrane proteins, get misfolded and how this can lead to diseases like cystic fibrosis. They use cutting-edge techniques to explore how the production, quality control, and mutations of these proteins affect cellular health. This research aims to develop better therapies for patients with genetic variants of cystic fibrosis by optimizing treatment strategies.

Dr. Luis Solorio's research lab focuses on combatting aggressive forms of cancer, such as pancreatic and breast cancer, by understanding and manipulating the tumor environment. The team is working on innovative strategies to enhance drug delivery directly to tumors and to disrupt the processes that allow cancer to spread to other parts of the body. They employ advanced engineering techniques and biological models to improve therapeutic outcomes for patients.

Robert Stahelin's lab at Purdue University focuses on studying deadly viruses like Ebola, Marburg, and SARS-CoV-2. They investigate how these viruses assemble and spread within human cells, aiming to discover new drug targets for treatment. The lab combines computational methods with experimental techniques to understand the viral proteins and their interactions, which is crucial for combating these significant public health threats.

Dr. Jennifer L Brown's lab at Purdue University focuses on improving healthcare strategies to prevent substance use disorders and overdoses. They are particularly interested in using emergency departments as a setting to screen patients for at-risk substance use and provide motivational interviewing and referrals to treatment. The lab aims to assess the effectiveness and feasibility of these approaches to help people who may not otherwise receive support for their substance use issues.

Dr. Shankar Thangamani's lab at Purdue University studies Candida auris, a drug-resistant fungus that colonizes the skin and can lead to severe infections in hospitalized patients. The lab focuses on understanding how the skin microbiota influences the growth of this fungus, aiming to uncover mechanisms that could inform new treatment strategies. By examining both the properties of the bacteria on the skin and the host's immune response, the research seeks to provide insights to combat these increasingly common infections.

Dr. Robert Graham Cooks leads a research lab at Purdue University focused on developing advanced methods for drug discovery using mass spectrometry. His team specializes in high-throughput screening, a powerful technique that allows for rapid analysis and synthesis of potential therapeutic compounds. The lab's innovative work aims to discover new treatments, particularly for advanced-stage prostate cancer, by efficiently combining chemical synthesis and biological testing.

Chongli Yuan's research lab at Purdue University focuses on understanding how environmental factors, particularly exposure to lead, interact with genetic risks and contribute to Alzheimer's disease and related dementia (AD/ADRD) as people age. Through innovative engineering and modeling techniques, the lab aims to shed light on the biological processes involved in these interactions. The lab utilizes advanced neuronal models to explore how exposure to lead during vulnerable developmental periods can lead to long-term neurological issues and offers insights into potential interventions.

Dr. Arun Ghosh's lab at Purdue University focuses on developing new treatments for HIV/AIDS, particularly through the design and synthesis of innovative protease inhibitors. These inhibitors aim to overcome challenges posed by drug-resistant strains of the virus and improve treatment for patients experiencing complications such as neurocognitive disorders. The lab employs advanced techniques in chemistry and biology to create more effective antiviral agents that are essential for long-term HIV management.

Dr. Elizabeth Ivy Parkinson's lab at Purdue University focuses on discovering novel medicine from soil bacteria called Streptomyces. They analyze the genetic blueprints of these bacteria to find hidden pathways that could lead to new bioactive compounds, specifically cyclic peptides. Another goal is to develop unique enzymes that can be used to create these promising compounds more efficiently, enhancing the laboratory's capability to synthesize and test potential new drugs.

Dr. Suresh K Mittal's lab at Purdue University focuses on developing innovative vaccines, particularly for COVID-19 and influenza. They aim to create a new adenoviral vaccine platform that is effective even in vulnerable populations, such as the elderly. The research also explores antibody-dependent enhancement and the immune response to these vaccines, which could contribute significantly to public health initiatives against pandemics.

Dr. Yoon Yeo's lab focuses on developing innovative drug delivery systems to treat eye diseases that cause blindness. They are particularly interested in repurposing the old antifungal drug griseofulvin to create long-acting formulations that can be injected into the eye for treating conditions like age-related macular degeneration. By using new polymer-based delivery methods, the lab aims to improve patient outcomes and convenience while reducing the cost of treatment.